The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor
  • This agreement covers the installation of new technology into Uscom’s device as it approaches regulatory approval in China and the United States
  • According to Uscom, BP+ provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms, which take be used on both the arm and the heart
  • The company says its device performs better than current tech used to manage hypertension, one of the leading causes of premature death in the world
  • Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each

Uscom (UCM) has signed a supply and development agreement with A&D Japan for the Uscom BP+ blood pressure monitor.

A&D (Analogue and Digital) are a Tokyo-based company that is engaged in the development, manufacture, and sale of measurement instruments in the medical and healthcare sector.

This agreement covers the installation of new technology from A&D in Uscom’s device as it approaches regulatory approval in China and the United States.

Uscom BP+ is a highly-accurate blood pressure monitor that can measure blood pressure waveforms in not only the arm but the heart.

It provides a highly accurate and repeatable measurement of central blood pressure and pulse pressure waveforms.

According to Uscom, BP+ is set to replace traditional blood pressure monitors and is the up-and-coming standard of care measurements for hypertension, heart failure, and general heart health.

“Current hypertensive management is poor, and we have developed the BP+ to advance the science in this common and dangerous condition,” Executive Chairman Associate Professor Rob Phillips stated.

“Quality technology is critical for our devices, and this new partnership with A&D allows Uscom to provide clinicians with the best tools for BP monitoring and hypertensive care,” he said.

Hypertension

According to the World Health Organisation (WHO), hypertension is one of the leading causes of premature death in the world.

It has estimated that of the 1.13 billion people who have it, only one in five has it under control.

WHO hopes to reduce the prevalence of hypertension by 25 per cent by 2025.

Hypertension, also known as high blood pressure, is a condition in which the force of the blood against the artery walls in the body is too high.

While hypertension typically has no symptoms, if it’s left untreated for a long period of time it can cause health conditions such as a stroke or heart disease.

Treatments include a healthier diet with less salt, quitting smoking, regular exercise, and medication.

Uscom shares are down a slight 4.35 per cent and are trading for 22 cents each at 1:49 pm AEST.

UCM by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…